Evidence b(i)ased medicine.

[Argirios Argiriou]

BMJ. 2003 May 31;326(7400):1171-3.

Evidence b(i)ased medicine--selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications.
Melander H, Ahlqvist-Rastad J, Meijer G, Beermann B.

Medical Products Agency, Box 23, S-751 03 Uppsala, Sweden. hans.melander@mpa.se

Abstract
OBJECTIVES: To investigate the relative impact on publication bias caused by multiple publication, selective publication, and selective reporting in studies sponsored by pharmaceutical companies. DESIGN: 42 placebo controlled studies of five selective serotonin reuptake inhibitors submitted to the Swedish drug regulatory authority as a basis for marketing approval for treating major depression were compared with the studies actually published (between 1983 and 1999). RESULTS: Multiple publication: 21 studies contributed to at least two publications each, and three studies contributed to five publications. Selective publication: studies showing significant effects of drug were published as stand alone publications more often than studies with non-significant results. Selective reporting: many publications ignored the results of intention to treat analyses and reported the more favourable per protocol analyses only. CONCLUSIONS: The degree of multiple publication, selective publication, and selective reporting differed between products. Thus, any attempt to recommend a specific selective serotonin reuptake inhibitor from the publicly available data only is likely to be based on biased evidence.

PMID: 12775615 [PubMed - indexed for MEDLINE]PMCID: PMC156459Free PMC Article


Δεν είναι ορατοί οι σύνδεσμοι (links). Εγγραφή ή Είσοδος

[Denominator]

Εξαιρετικό σκωπτικό άρθρο, πιστεύω ότι αξίζει να διαβαστεί - σε κάποια σημεία ενδέχεται να συναντήσουμε και δικές μας πτυχές στην άσκηση της ιατρικής:

Seven Alternatives to Evidence-Based Medicine
David Isaacs and Dominic Fitzgerald
Δεν είναι ορατοί οι σύνδεσμοι (links). Εγγραφή ή Είσοδος